Michael D Tarantino1, James B Bussel2, Victor S Blanchette3, Jenny Despotovic4, Carolyn Bennett5, Ashok Raj6, Bronwyn Williams7, Donald Beam8, Jaime Morales9, Melissa J Rose10, Nancy Carpenter11, Kun Nie12, Melissa Eisen12. 1. The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, IL, USA. Electronic address: mtarantino@ilbcdi.org. 2. Department of Pediatrics, Division of Hematology, Weill Cornell Medicine, New York, NY, USA. 3. Hospital for Sick Children, Toronto, ON, Canada. 4. Texas Children's Hematology Center, Houston, TX, USA. 5. Emory University School of Medicine, Children's Healthcare of Atlanta and the Aflac Cancer and Blood Disorder Service, Atlanta, GA, USA. 6. Pediatric Blood and Cancer Disorders Clinic, Louisville, KY, USA. 7. Lady Cilento Children's Hospital, South Brisbane, QLD, Australia. 8. Cook Children's Medical Center, Texas, TX, USA. 9. Children's Hospital New Orleans and Louisiana State University Health Sciences Center, New Orleans, LA, USA. 10. Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH, USA. 11. Amgen Ltd, Uxbridge, UK. 12. Amgen Inc, Thousand Oaks, CA, USA.
Abstract
BACKGROUND: The thrombopoietin receptor agonist romiplostim could be an effective treatment in symptomatic children with persistent or chronic immune thrombocytopenia. We aimed to assess whether romiplostim is safe and effective in children with immune thrombocytopenia of more than 6 months' duration. METHODS: In this phase 3 double-blind study, eligible participants were children with immune thrombocytopenia aged 1 year to 17 years and mean platelet counts 30 × 10(9)/L or less (mean of two measurements during the screening period) with no single count greater than 35 × 10(9)/L, and were recruited from 27 sites in the USA, Canada, and Australia. Participants were randomly assigned (2:1) through the interactive voice response system to receive weekly romiplostim or placebo for 24 weeks stratified by age (1 year to <6 years, 6 years to <12 years, 12 years to <18 years), adjusting the dose weekly from 1 μg/kg to 10 μg/kg to target platelet counts of 50-200 × 10(9)/L. Patients and investigators were blinded to the treatment assignment. The primary analysis included all randomised patients and the safety analysis included all randomised patients who received at least one dose of investigational product. The primary endpoint, durable platelet response, was defined as achievement of weekly platelet responses (platelet counts ≥50 × 10(9)/L without rescue drug use in the preceding 4 weeks) in 6 or more of the final 8 weeks (weeks 18-25). This study is registered with ClinicalTrials.gov, NCT 01444417. FINDINGS:Between Jan 24, 2012, and Sept 3, 2014, 62 patients were randomly assigned; 42 to romiplostim and 20 toplacebo. Durable platelet response was seen in 22 (52%) patients in the romiplostim group and two (10%) in the placebo group (p=0·002, odds ratio 9·1 [95% CI 1·9-43·2]). Durable platelet response rates with romiplostim by age were 38% (3/8) for 1 year to younger than 6 years, 56% (10/18) for 6 years to younger than 12 years, and 56% (9/16) for 12 years to younger than 18 years. One (5%) of 19 patients in the placebo group had serious adverse events compared with 10 (24%) of 42 patients in the romiplostim group. Of these serious adverse events, headache and thrombocytosis, in one (2%) of 42 patients in the romiplostim group, were considered treatment related. No patients withdrew due to adverse events. INTERPRETATION: In children with chronic immune thrombocytopenia, romiplostim induced a high rate of platelet response with no new safety signals. Ongoing romiplostim studies will provide further information as to long-term efficacy, safety, and remission in children with immune thrombocytopenia. FUNDING: Amgen Inc.
RCT Entities:
BACKGROUND: The thrombopoietin receptor agonist romiplostim could be an effective treatment in symptomatic children with persistent or chronic immune thrombocytopenia. We aimed to assess whether romiplostim is safe and effective in children with immune thrombocytopenia of more than 6 months' duration. METHODS: In this phase 3 double-blind study, eligible participants were children with immune thrombocytopenia aged 1 year to 17 years and mean platelet counts 30 × 10(9)/L or less (mean of two measurements during the screening period) with no single count greater than 35 × 10(9)/L, and were recruited from 27 sites in the USA, Canada, and Australia. Participants were randomly assigned (2:1) through the interactive voice response system to receive weekly romiplostim or placebo for 24 weeks stratified by age (1 year to <6 years, 6 years to <12 years, 12 years to <18 years), adjusting the dose weekly from 1 μg/kg to 10 μg/kg to target platelet counts of 50-200 × 10(9)/L. Patients and investigators were blinded to the treatment assignment. The primary analysis included all randomised patients and the safety analysis included all randomised patients who received at least one dose of investigational product. The primary endpoint, durable platelet response, was defined as achievement of weekly platelet responses (platelet counts ≥50 × 10(9)/L without rescue drug use in the preceding 4 weeks) in 6 or more of the final 8 weeks (weeks 18-25). This study is registered with ClinicalTrials.gov, NCT 01444417. FINDINGS: Between Jan 24, 2012, and Sept 3, 2014, 62 patients were randomly assigned; 42 to romiplostim and 20 to placebo. Durable platelet response was seen in 22 (52%) patients in the romiplostim group and two (10%) in the placebo group (p=0·002, odds ratio 9·1 [95% CI 1·9-43·2]). Durable platelet response rates with romiplostim by age were 38% (3/8) for 1 year to younger than 6 years, 56% (10/18) for 6 years to younger than 12 years, and 56% (9/16) for 12 years to younger than 18 years. One (5%) of 19 patients in the placebo group had serious adverse events compared with 10 (24%) of 42 patients in the romiplostim group. Of these serious adverse events, headache and thrombocytosis, in one (2%) of 42 patients in the romiplostim group, were considered treatment related. No patients withdrew due to adverse events. INTERPRETATION: In children with chronic immune thrombocytopenia, romiplostim induced a high rate of platelet response with no new safety signals. Ongoing romiplostim studies will provide further information as to long-term efficacy, safety, and remission in children with immune thrombocytopenia. FUNDING: Amgen Inc.
Authors: Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert Journal: Am J Hematol Date: 2018-05-06 Impact factor: 10.047
Authors: Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter Journal: Blood Adv Date: 2019-11-26
Authors: Elena V Suntsova; Irina M Demina; Anastasia A Ignatova; Nikolay M Ershov; Natalia M Trubina; Juliya Dobrynina; Irina V Serkova; Zhanna S Supik; Ekaterina V Orekhova; Lili A Hachatryan; Natalia N Kotskaya; Aleksey V Pshonkin; Aleksey A Maschan; Galina A Novichkova; Mikhail A Panteleev Journal: Int J Hematol Date: 2017-03-07 Impact factor: 2.490